Second EUMelaReg poster at SMR congress 2023
We are proud that another EUMelaReg project was accepted for poster presentation at the SMR congress this year: “Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment”. The development of immune checkpoint inhibitors (ICI) and targeted therapy with BRAF and MEK inhibitors, has improved the treatment of unresectable and metastatic melanoma dramatically in recent years. Postoperative treatment of patients with either anti-PD1 antibodies or BRAF and MEK inhibitors in the adjuvant setting results in better recurrence free survival rates and has therefore become the standard of care for the majority of resected stage III melanoma, particularly stage IIIB/IID. Currently, there is insufficient evidence regarding efficacy of anti-PD1 antibodies in patients who need systemic treatment after failure of adjuvant ICI. The clinical characteristics outcome of patients who underwent non adjuvant anti-PD1 treatment with pembrolizumab after failure of adjuvant anti-PD1 therapy were evaluated in 74 patients who were identified from the EUMelaReg and eligible for this analysis.